Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
30.48
May 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 28.26 - 45.45
Open     -
Vol / Avg. 0.00/648,220.00
Mkt cap 1.35B
P/E 93.22
Div/yield     -
EPS 0.33
Shares 42.79M
Beta 1.19
Inst. own 110%
Jul 29, 2015
Q2 2015 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 9, 2015
Acorda Therapeutics Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Jun 5, 2015
Acorda Therapeutics Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Jun 2, 2015
Acorda Therapeutics Inc at Jefferies Global Healthcare Conference - 3:30PM EDT - Add to calendar
May 12, 2015
Acorda Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Acorda Therapeutics Inc at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Acorda Therapeutics Inc Earnings Release
Apr 30, 2015
Q1 2015 Acorda Therapeutics Inc Earnings Call
Mar 11, 2015
Acorda Therapeutics Inc at Barclays Healthcare Conference - Webcast
Mar 2, 2015
Acorda Therapeutics Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -3.09% 4.40%
Operating margin -1.26% 9.06%
EBITD margin - 12.92%
Return on average assets -1.14% 2.09%
Return on average equity -2.27% 3.60%
Employees 489 -
CDP Score - -

Address

420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. (Acorda) is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company’s Ampyra (dalfampridine) is used as a treatment to improve walking in patients with MS. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride. The Company is developing six clinical-stage therapies and one pre-clinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. It is also developing Plumiaz (trade name for Diazepam Nasal Spray), a nasal spray formulation of diazepam, for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 42
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 57
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 51
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters